Comparative Pharmacology
Head-to-head clinical analysis: DULERA versus HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DULERA versus HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1.
DULERA vs HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
Hydrocortisone acetate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, vasodilation, and immune cell activity. Pramoxine hydrochloride is a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, inhibiting nerve impulse conduction and providing topical anesthesia.
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
Apply a thin film to affected area three to four times daily. Topical only.
None Documented
None Documented
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
Hydrocortisone acetate: 1.5–2 hours (plasma), clinically adrenocortical suppression lasts 24–48 hours; pramoxine: not applicable due to minimal absorption.
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Hydrocortisone acetate: primarily renal (about 90% as metabolites, less than 1% unchanged); pramoxine HCl: negligible systemic absorption, eliminated primarily via fecal excretion.
Category C
Category D/X
Corticosteroid/Beta2-Agonist Combination
Corticosteroid